Bovigen Scour Emulsion For Injection For Cattle
Revised: February 2016
SUMMARY OF PRODUCT CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
BOVIGEN SCOUR (AT, BE, DR, EE, FR, IE, IT, LV, LT, LU, NL, PT, RO, UK)
BOVIGEN RCE Vet(FI, NO, SE)
Emulsion for injection for cattle
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
One dose of the vaccine (3 ml) contains:
Bovine rotavirus strain TM-91, serotype G6P1 (inactivated) ≥ 6.0 log2(VNT)*
Bovine coronavirus strain C-197 (inactivated) ≥ 5.0 log2(HIT)**
Escherichia colistrain EC/17 (inactivated)
expressing F5 (K99) adhesin ≥ 44.8% of inhibition (ELISA)***
*VNT – virus neutralisation test (rabbit serology induced by 2/3 dose of vaccine).
**HIT – haemagglutination inhibition test (rabbit serology induced by 2/3 dose of vaccine).
***ELISA – Enzyme-linked immunosorbent assay (rabbit serology induced by 2/3 dose of vaccine).
Montanide ISA 206 VG 1.6 ml
Formaldehyde max. 1.5 mg
Thiomersal max. 0.36 mg.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Emulsion for injection.
White liquid emulsion which may form a sediment during storage.
4. CLINICAL PARTICULARS
4.1 Target species
Cattle (pregnant cows and heifers)
4.2 Indications for use, specifying the target species
For the active immunisation of pregnant cows and heifers to raise antibodies against E. coli adhesion F5 (K 99) antigen, rotavirus and coronavirus. When calves are fed colostrum from vaccinated cows during the first week of life, these antibodies have been demonstrated to reduce the severity of diarrhoea caused by bovine rotavirus, bovine coronavirus and enteropathogenic E. coli F5 (K99) and to reduce the shedding of virus by calves infected with bovine rotavirus or bovine coronavirus.
Onset of immunity: Passive immunity commences with colostrum feeding and is dependent on calves receiving sufficient colostrum after birth.
4.4 Special warnings
4.5 Special precautions for use
Special precautions for use in animals
Vaccinate healthy animals only.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
To the user:
This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.
To the physician:
This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.
4.6 Adverse reactions (frequency and seriousness)
A slight swelling of 5–7 cm in diameter at the site of injection is common (more than 1 but less than 10 animals in 100 animals), and may in some cases be accompanied initially by increased local temperature. Typically, such swelling resolves within 15 days.
Slight, transient increases in temperature (up to 0.8 °C) may be observed within 24 hours of vaccination, resolving within 4 days after vaccination.
4.7 Use during pregnancy, lactation, or lay
This veterinary medicinal product is intended for use in the last trimester of pregnancy.
4.8 Interaction with other medicinal products and other forms of interaction
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.
4.9 Amounts to be administered and administration route
For intramuscular use.
Common aseptic procedures should be used during vaccination.
Only sterile syringes and needles should be used.
Allow the vaccine to reach room temperature before use. Shake well before and occasionally during use to ensure that the sediment is dissolved prior to administration.
One dose: 3 ml.
Primary vaccination: 2 doses - the first dose in the 12–5 week period before calving is expected and the second dose three weeks after the first dose.
Revaccination: One dose in the course of each pregnancy, given in the 12–3 week period before calving is expected.
Feeding of colostrum
The protection of calves depends on adequate ingestion of colostrum from vaccinated cows. Measures should be taken to ensure that calves receive sufficient amounts of colostrum within the first few days of life. If calves do not get enough antibodies through the colostrum soon after they are born, they will have failure of passive transfer of antibodies. It is important that all calves receive sufficient amounts of colostrum from the first milking within the first six hours after calving. It is recommended that 3 litres are fed at the first feed for calves with a weight of 35–45 kg (e.g. Holstein-Friesian type dairy calves). For very small calves (e.g. Jerseys), 2–2.5 litres is adequate.
To achieve optimum results and to reduce infection pressure on the farm, a whole herd cow vaccination policy should be adopted.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Following the administration of an overdose, no adverse reactions other than those mentioned in section 4.6 occur.
4.11 Withdrawal period(s)
5. IMMUNOLOGICAL PROPERTIES
Pharmacotherapeutic group: immunologicals for Bovidae, inactivated viral and inactivated bacterial vaccines for cattle.
ATCvet code: QI02AL01.
The vaccine is designed for stimulation of the active immunity of pregnant cows against the antigenic components included in the vaccine. The antibodies are transferred to the calf via colostrum.
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Montanide ISA 206 VG
Eagle’s minimum essential medium (MEM)
Disodium phosphate dodecahydrate
Potassium dihydrogen phosphate
Water for injections
Do not mix with any other veterinary medicinal product.
6.3 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the immediate packaging: 10 hours.
6.4. Special precautions for storage
Store in a refrigerator (2 °C – 8 °C). Protect from light. Do not freeze.
6.5 Nature and composition of immediate packaging
Cardboard box containing one type I glass vial (15 ml, 90 ml) closed with chlorobutyl rubber stopper or one type I glass bottle (450 ml) closed with bromobutyl rubber stopper sealed with aluminium cap.
Low density polyethylene (LDPE) bottles (450 ml) closed with chlorobutyl rubber stopper and sealed with aluminium cap without outer package.
For packing of 90 ml and 450 ml respectively it is recommended to use automated dosing equipment to protect stopper against destruction by multi-piercing.
Cardboard box with 1 vial of 15 ml (5 doses).
Cardboard box with 1 vial of 90 ml (30 doses).
Cardboard box with 1 glass bottle of 450 ml (150 doses).
Plastic bottle with 450 ml (150 doses).
Not all pack sizes may be marketed.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER
Forte Healthcare Ltd
Republic of Ireland
8. MARKETING AUTHORISATION NUMBER
9. DATE OF FIRST AUTHORISATION
30 April 2015
10. DATE OF REVISION OF THE TEXT
PROHIBITION OF SALE, SUPPLY AND/OR USE
23 February 2016
Page 5 of 5